Results 71 to 80 of about 13,238,937 (304)

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

Parkinson's Disease, 2015
Objectives. To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating
Fabrizio Stocchi, Laura Vacca, Paola Grassini, Stephen Pawsey, Holly Whale, Stefano Marconi, Margherita Torti   +6 more
doaj   +1 more source

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease

Molecules, 2017
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and less than 1% of the oral dose is ...
Monique Hoon, Jacobus P. Petzer, Francois Viljoen, Anél Petzer   +3 more
doaj   +1 more source

Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

Journal of Parkinson’s Disease, 2022
Background: L-DOPA-induced dyskinesia (LID), occurring with aberrant processing of exogenous L-DOPA in the dopamine-denervated striatum, is a main complication of levodopa treatment in Parkinson’s disease.
Kuan-Yin Tseng, Tung-Tai Kuo, Vicki Wang, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Lars Olson, Barry J. Hoffer, Yuan-Hao Chen   +7 more
doaj   +1 more source

Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease

Advanced Science, EarlyView.
LRRK2‐mutant induced pluripotent stem cells (iPSCs) were derived from a patient with Parkinson's disease (PD). Using CRISPR/Cas9–mediated gene editing, the pathogenic LRRK2 mutations were precisely corrected, and isogenic dopaminergic neural progenitor cells (DA‐NPCs) were subsequently generated.
Qing Yan, Chongchong Xu, Jiangmei Gao, Pu Wang, Qingling Wu, Ying Jin, Binyan Lu, Mu Li, Mingting Shao, Bihai Li, Zhenghui Su, Yijng Zhang, Jianhuan Chen, Haojie An, Mengyao Huang, Xiaoji Zhuang, Yuhui Shen, Fenglin Wang, Nana Xu, Yiyan Liu, Lei Tang, Xiuling Zhong, Minyan Zhong, Jiecong Chen, Zhenhuang Wang, Xingrong Luo, Sheng Liu, RuiFeng Liu, Ling Zhang, Junhua Rao   +29 more
wiley   +1 more source

The Effect of Chronic Treatment with the Inhibitor of Phosphodiesterase 5 (PDE5), Sildenafil, in Combination with L-DOPA on Asymmetric Behavior and Monoamine Catabolism in the Striatum and Substantia Nigra of Unilaterally 6-OHDA-Lesioned Rats

Molecules
The use of phosphodiesterase inhibitors in the treatment of Parkinson’s disease is currently widely discussed. The study aimed to investigate the impact of acute and chronic treatment with the phosphodiesterase 5 inhibitor, sildenafil, at low and ...
Elżbieta Lorenc-Koci, Kinga Kamińska, Tomasz Lenda, Jolanta Konieczny   +3 more
doaj   +1 more source

Fluoxetine Improves the Effect of Levodopa on 6-Hydroxy Dopamine-Induced Motor Impairments in Rats [PDF]

Advanced Pharmaceutical Bulletin, 2012
Purpose: Long term L-DOPA therapy in Parkinson’s disease is associated with troublesome motor fluctuations such as L -DOPA Induced dyskinesia and wearing off effect.
Javad Mahmoudi, Alireza Mohajjel Nayebi, Siyamak Reyhani-Rad, Morteza Samini   +3 more
doaj  

L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain

Parkinson's Disease, 2012
Astrocyte endfeet surround brain blood vessels and can play a role in the delivery of therapeutic drugs for Parkinson’s disease. However, there is no previous evidence of the presence of LAT transporter for L-DOPA in brain astrocytes except in culture ...
M. Y. Inyushin, A. Huertas, Y. V. Kucheryavykh, L. Y. Kucheryavykh, V. Tsydzik, P. Sanabria, M. J. Eaton, S. N. Skatchkov, L. V. Rojas, W. D. Wessinger   +9 more
doaj   +1 more source

Effects of Subchronic Treatment With Selegiline on L-DOPA-Induced Increase in Extracellular Dopamine Level in Rat Striatum

Journal of Pharmacological Sciences, 2006
.: Selegiline is used an adjunct to L-DOPA therapy. We investigated extracellular striatal dopamine (DA) level in awake rats treated with L-DOPA and/or selegiline using a microdialysis method. Rats given 10 mg/kg, i.p.
Adachi Kouichi, Miwa Hideto, Kusumoto Haruko, Shimazu Seiichiro, Kondo Tomoyoshi   +4 more
doaj   +1 more source

Pramipexole in comparison to l-dopa: a neuropsychological study

, 2003
Twenty right-handed patients affected by early/mild Parkinson's disease were evaluated in a randomised study using neuropsychological and clinical assessements during three treatment modalities: when in the off treatment condition, when on pramipexole ...
Pierantozzi, M, Peppe, A, Brusa, L, Stanzione, P, Stefani, A, Ruggieri, S, Caramia, M, STEFANI, ALESSANDRO, PIERANTOZZI, MARIANGELA, Boffa, L, STANZIONE, PAOLO, Bassi, A   +11 more
core   +1 more source

Multi‐tissue Metabolic GWAS and Drought‐Responsive Multi‐omics Reveal the Genetic Basis of the Quinoa Metabolome

Advanced Science, EarlyView.
A multi‐omics framework combining multitissue genome‐wide association studies, metabolomics, transcriptomics, proteomics, and functional validation uncovers the genetic basis of specialized metabolism in quinoa. The study identifies hundreds of metabolite‐associated loci, prioritizes candidate genes for saponin, betalain, and flavonoid biosynthesis ...
Julia von Steimker, Elodie L. Rey, Clara Stanschewski, Regina Wendenburg, Annabella Klemmer, Markéta Macho, Venkatesh P. Thirumalaikumar, Noha O. Saber, Aleksandra Skirycz, Alisdair R. Fernie, Mark Tester, Saleh Alseekh   +11 more
wiley   +1 more source